Seeing Is Believing
Currently out of the existing stock ratings of Matthew Andrews, 26 are a BUY (89.66%), 3 are a HOLD (10.34%).
Analyst Matthew Andrews, carries an average stock price target met ratio of 71.04% that have a potential upside of 34.89% achieved within 164 days. Previously, Matthew Andrews worked at JEFFERIES.
Matthew Andrews’s has documented 58 price targets and ratings displayed on 8 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on AMRN, Amarin PLC at 24-Sep-2018.
Analyst best performing recommendations are on SPPI (SPECTRUM PHARMACEUTICALS).
The best stock recommendation documented was for SPPI (SPECTRUM PHARMACEUTICALS) at 9/25/2017. The price target of $13 was fulfilled within 3 days with a profit of $3.16 (32.11%) receiving and performance score of 107.05.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
$2
$-5.5 (-73.33%)
$18
7 years 2 months 3 days ago
(13-Aug-2018)
3/4 (75%)
$0.34 (20.48%)
130
Hold
$2
$-5.5 (-73.33%)
$30
7 years 2 months 6 days ago
(10-Aug-2018)
1/3 (33.33%)
$14.2 (165.52%)
27
What Year was the first public recommendation made by Matthew Andrews?